Method to treat cancer with engineered T-cells
US10639329B2 · kind B2 · utility
6Cited by
77References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 12, 2016 |
| Grant date | May 5, 2020 |
| Priority date | — |
| Expiry date | Jun 12, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel adoptive immunotherapy compositions comprising co-cultured lentiviral vector-transduced autologous antigen presentation cells and T cells are provided herein as well as are methods of use of same in a patient-specific combination immunotherapy that can be used to treat cancers and other diseases and conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.